Glaucoma drug taprenepag finds success; Depomed receives $5M in milestones

 @FierceBiotech: The Top 10 Phase III Failures of 2010. Article | Follow @FierceBiotech

 @JohnCFierce: Lilly gets hit again. Teplizumab fails Ph3 for diabetes. MacroGenics gets hurt on this one as well. Article | Follow @JohnCFierce

> Taprenepag, the first of a new class of glaucoma drugs, performed well in a Phase II clinical trial. When combined with the current standard glaucoma treatment, the medications lowered IOP more effectively than either treatment alone. News

> Janssen Pharmaceutica has paid Depomed $5 million in milestone payments for canagliflozin and metformin. Depomed release

> Novartis and Emisphere Technologies announced the first interpretable results from its Phase III trial of osteoarthritis treatment oral calcitonin. Of the three primary endpoints, the drug appears it will meet two, but not the first endpoint, narrowing joint width space. Novartis and Nordic Bioscience will continue analyzing the results while the trial continues. Emisphere release

> Live from AdvaMed: The do's and don'ts of FDA inspections. Report 

> The European Medicines Agency has recommended AstraZeneca's nasal flu vaccine, FluMist, be approved for children's use. The vaccine, which has been approved in the U.S. since 2003, could be sold in Europe as soon as Fall 2012. The next step towards approval will be the European Commission's endorsement of the recommendation. Article

> While the NFL is fining and suspending players for illegal hard hits, the league also is looking with great interest with at a new test from Banyan Biomarkers that could help diagnose concussions. Story

And Finally... Broccoli's cancer-fighting component can be utilized without eating--or overcooking--the vegetable. Scientists at the University of Illinois have injected sulforaphane into the cecums of rats, and the anti-cancer component is absorbed by their bodies. Release

Suggested Articles

CureVac named a permanent CEO, Franz-Werner Haas, and signed Novartis alum, Igor Splawski, Ph.D. as its new top scientist.

J&J studied the drug in midphase obesity clinical trials, but Merck sees it as a potential treatment for nonalcoholic steatohepatitis.

The Big Pharma paid $134 million to enter into the two partnerships but then dropped the projects after Voyager completed research activities.